American Cancer Society (2024) Cancer Facts& Figures 2024. In: Am. Cancer Soc. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf. Accessed 6 May 2024

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263. https://doi.org/10.3322/caac.21834

Article  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12–49. https://doi.org/10.3322/caac.21820

Article  PubMed  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Lou SM, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R (2024) Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22:331–357. https://doi.org/10.6004/jnccn.2024.0035

Article  PubMed  Google Scholar 

Sparano JA, Wang M, Martino S, Jones V, Perez E, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE (2007) Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. J Clin Oncol 25:516. https://doi.org/10.1200/jco.2007.25.18_suppl.516

Article  Google Scholar 

Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18:132–138. https://doi.org/10.1007/s10147-011-0352-x

Article  PubMed  Google Scholar 

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL (2018) Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res 24:3602–3610. https://doi.org/10.1158/1078-0432.CCR-18-0656

Article  PubMed  PubMed Central  Google Scholar 

Zajaczkowską R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J (2019) Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 20:1451. https://doi.org/10.3390/ijms20061451

Article  PubMed  PubMed Central  Google Scholar 

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Lou SM, Smith TJ, Wagner-Johnston N, Hershman DL (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325–3348. https://doi.org/10.1200/JCO.20.01399

Article  PubMed  Google Scholar 

Duggett NA, Griffiths LA, Flatters SJL (2017) Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons. Pain 158:1499–1508. https://doi.org/10.1097/j.pain.0000000000000939

Article  PubMed  PubMed Central  Google Scholar 

Shemesh OA, Spira ME (2010) Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: Implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 119:235–248. https://doi.org/10.1007/s00401-009-0586-0

Article  PubMed  Google Scholar 

Al-Mazidi S, Alotaibi M, Nedjadi T, Chaudhary A, Alzoghaibi M, Djouhri L (2018) Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy-induced neuropathy. Eur J Pain 22:810–821. https://doi.org/10.1002/ejp.1169

Article  PubMed  Google Scholar 

Ma D, Wang X, Liu X, Li Z, Liu J, Cao J, Wang G, Guo Y, Zhao S (2022) Macrophage infiltration initiates RIP3/MLKL-dependent necroptosis in paclitaxel-induced neuropathic pain. Mediat Inflamm 2022:1–10. https://doi.org/10.1155/2022/1567210

Article  Google Scholar 

Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, Hashemzade S, Asghari Jafarabadi M, Montazeri V, Keshavarz SA, Darabi M (2012) Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 12:355. https://doi.org/10.1186/1471-2407-12-355

Article  PubMed  PubMed Central  Google Scholar 

Khalefa HG, Shawki MA, Aboelhassan R, El Wakeel LM (2020) Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study. Breast Cancer Res Treat 183:117–125. https://doi.org/10.1007/s10549-020-05762-8

Article  PubMed  Google Scholar 

Haroun EA, Mansour NO, Eltantawy A, Shams MEE (2023) Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: a randomized controlled trial. Pharmacotherapy 43:872–882. https://doi.org/10.1002/phar.2830

Article  PubMed  Google Scholar 

Bakry HM, Mansour NO, ElKhodary TR, Soliman MM (2023) Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial. Front Pharmacol 14:1181312. https://doi.org/10.3389/fphar.2023.1181312

Article  PubMed  PubMed Central  Google Scholar 

Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, Le Rhun E, Preusser M, Scotté F, Taphoorn MJB, Jordan K (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003

Article  PubMed  Google Scholar 

Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66–72. https://doi.org/10.1016/0002-8703(82)90642-1

Article  PubMed  Google Scholar 

Garcia FAO, Rebouças JF, Balbino TQ, Da Silva TG, De Carvalho-Júnior CHR, Cerqueira GS, Brito GAC, Viana GSB (2015) Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase. J Inflamm 12:33. https://doi.org/10.1186/s12950-015-0080-5

Article  Google Scholar 

Kreth S, Ledderose C, Luchting B, Weis F, Thiel M (2010) Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 34:10–16. https://doi.org/10.1097/SHK.0b013e3181cdc3e2

Article  PubMed  Google Scholar 

Pindiprolu SKSS, Krishnamurthy PT, Ks N, Chintamaneni PK, Bhadri N, Razdan R (2019) Protective effects of pentoxifylline against oxaliplatin induced neuropathy. Lat Am J Pharm 38:177–181

Google Scholar 

Kim HK, Hwang SH, Lee SO, Kim SH, Abdi S (2016) Pentoxifylline ameliorates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain. Pain Physician 19:E589–E600

PubMed  Google Scholar 

Liu J, Feng X, Yu M, Xie W, Zhao X, Li W, Guan R, Xu J (2007) Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett 412:268–272. https://doi.org/10.1016/j.neulet.2006.11.022

Article  PubMed  Google Scholar 

Baykal S, Boz C, Çakir E, Baytan TH, Karaku M, Kuzeylý K (2002) The effects of pentoxifylline in experimental nerve injury. Turk J Med Sci 32:207–210

Google Scholar 

Hosseini F, Mohammadbeigi A, Aghaali M, Borujerdi R, Parham M (2019) Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: a randomized trial. J Res Med Sci 24:89. https://doi.org/10.4103/jrms.JRMS_15_18

Article  PubMed  PubMed Central  Google Scholar 

McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Friedlander M, Bosco A, Harrison M, Maier N, O’Neill S, Park SB (2019) Optimizing clinical screening for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manag 58:1023–1032. https://doi.org/10.1016/j.jpainsymman.2019.07.021

Article  Google Scholar 

Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741–748. https://doi.org/10.1111/j.1525-1438.2003.13603.x

Article  PubMed  Google Scholar 

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627–2633. https://doi.org/10.1200/JCO.2012.44.8738

Article  PubMed  PubMed Central  Google Scholar 

Fernandes JL, de Oliveira RTD, Mamoni RL, Coelho OR, Nicolau JC, Blotta MHSL, Serrano CVJ (2008) Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease—a randomized placebo-controlled study. Atherosclerosis 196:434–442. https://doi.org/10.1016/j.atherosclerosis.2006.11.032

Article  PubMed